Protease Inhibitors for Recurrent Hepatitis C after Liver Transplantation-When Less is More
Section of Gastroenterology and Hepatology, Nebraska Medical Center, USA
- *Corresponding Author:
- Dr. Sandeep Mukherjee
Section of Gastroenterology and Hepatology
Nebraska Medical Center
Omaha, NE 68198-3285, USA
E-mail: [email protected]
Received Date: December 22, 2011; Accepted Date: December 24, 2011; Published Date: December 26, 2011
Citation: Mukherjee S (2012) Protease Inhibitors for Recurrent Hepatitis C after Liver Transplantation-When Less is More. J Antivir Antiretrovir 4: i-i. doi: 10.4172/jaa.1000e101
Copyright: © 2012 Mukherjee S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The approval of boceprevir and telaprevir, two protease inhibitors for hepatitis C (HCV) treatment earlier this year, was met with virtually universal optimism as the addition of these medications will lead to a significantly improved chance of viral eradication in HCV genotype 1 patients. However, this enthusiasm is yet to be embraced by the liver transplant community primarily due to the interaction between protease inhibitors and calcineurin inhibitors such as cyclosporine and tacrolimus. Boceprevir and telaprevir inhibit cytochrome P450 3A which metabolizes cyclosporine and tacrolimus leading to elevated and potentially lethal levels of these calcineurin inhibitors.